METHODS We reviewed the prospectively collected Pragmatic, Randomized Optimal
Platelet and Plasma Ratios database. We included patients with admission hyperfibrinolysis …

BACKGROUND In 2011, supported by data from two separate trauma centers, we
implemented a protocol to administer tranexamic acid (TXA) in trauma patients with …

The CRASH-2 trial results have prompted trauma centers to contemplate whether
tranexamic acid (TXA) should be added to their armamentarium for the treatment of bleeding …

BACKGROUND The association between tranexamic acid (TXA) and fibrinolysis shutdown
is unknown. We hypothesize that TXA is associated with fibrinolysis shutdown in critically …

Background Tranexamic acid (TXA) administration after trauma has not been proven to
improve survival in the United States. Trauma patients were presented to the hospital with a …

Fibrinolysis activation occurs almost universally after severe trauma. Systemic
hyperfibrinolysis is a key component of acute traumatic coagulopathy and associated with …

Background: Tranexamic acid (TXA) administration is recommended in severely injured
trauma patients. We examined TXA administration, admission fibrinolysis phenotypes, and …

Methods The Cal-PAT study is a multi-centered, prospective, observational cohort study with
a retrospective comparison. From March 2015 to July 2017, patients≥ 18 years-old who …

Tranexamic acid (TXA) reduces blood loss by inhibiting the enzymatic breakdown of fibrin. It
is often used in surgery to decrease bleeding and the need for blood transfusion. In 2011 …

Background Urgent treatment with tranexamic acid (TXA) reduces bleeding deaths but there
is disagreement about which patients should be treated. We examine the effects of TXA …